WO1994002103A3 - Ovulation inhibitor for hormonal contraception - Google Patents

Ovulation inhibitor for hormonal contraception Download PDF

Info

Publication number
WO1994002103A3
WO1994002103A3 PCT/DE1993/000656 DE9300656W WO9402103A3 WO 1994002103 A3 WO1994002103 A3 WO 1994002103A3 DE 9300656 W DE9300656 W DE 9300656W WO 9402103 A3 WO9402103 A3 WO 9402103A3
Authority
WO
WIPO (PCT)
Prior art keywords
estrogen
hormonal
components
component
gestagen
Prior art date
Application number
PCT/DE1993/000656
Other languages
German (de)
French (fr)
Other versions
WO1994002103A2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to EP93915661A priority Critical patent/EP0651644A1/en
Priority to JP6504082A priority patent/JPH07509454A/en
Priority to AU45583/93A priority patent/AU4558393A/en
Publication of WO1994002103A2 publication Critical patent/WO1994002103A2/en
Publication of WO1994002103A3 publication Critical patent/WO1994002103A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An ovulation inhibitor for hormonal contraception has two hormonal components separately arranged in a packaging unit for successive oral administration. Each hormonal component consists of a number of separately arranged hormonal daily units which can be individually taken from the packaging unit. One hormonal component (estrogen component) contains as hormonal active substance almost exclusively an estrogen preparation which prevents the follicle from ripening and the other hormonal component (estrogen-gestagen component) contains an estrogen preparation combined with a dose of a gestagen preparation at least sufficient for inhibiting ovulation. The ovulation inhibitor is characterized in that it has one or more estrogen components in 5 to 14 daily units that alternate with one or more estrogen-gestagen components in 23 to 14 daily units. The number of estrogen components is smaller than the number of daily units of estrogen-gestagen components. In the case where ethinyl estradiol is used as estrogen preparation, the dose of ethinyl estradiol per daily unit amounts to maximum 30νg.
PCT/DE1993/000656 1992-07-24 1993-07-26 Ovulation inhibitor for hormonal contraception WO1994002103A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93915661A EP0651644A1 (en) 1992-07-24 1993-07-26 Ovulation inhibitor for hormonal contraception
JP6504082A JPH07509454A (en) 1992-07-24 1993-07-26 Ovulation suppressants for hormonal contraception
AU45583/93A AU4558393A (en) 1992-07-24 1993-07-26 Ovulation inhibitor for hormonal contraception

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4224534.6 1992-07-24
DE4224534A DE4224534A1 (en) 1992-07-24 1992-07-24 Anti-ovulation agent for hormonal contraception

Publications (2)

Publication Number Publication Date
WO1994002103A2 WO1994002103A2 (en) 1994-02-03
WO1994002103A3 true WO1994002103A3 (en) 1994-05-11

Family

ID=6464040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1993/000656 WO1994002103A2 (en) 1992-07-24 1993-07-26 Ovulation inhibitor for hormonal contraception

Country Status (6)

Country Link
EP (1) EP0651644A1 (en)
JP (1) JPH07509454A (en)
AU (1) AU4558393A (en)
CA (1) CA2140011A1 (en)
DE (1) DE4224534A1 (en)
WO (1) WO1994002103A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (en) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component
DE19504227C2 (en) * 1995-02-09 1999-04-29 Klaus Dr Med Umbreit Anti-ovulation agent for hormonal contraception
DE19525017A1 (en) * 1995-06-28 1997-01-02 Schering Ag Pharmaceutical combination preparation, kit and method for hormonal contraception
DE19540253C2 (en) * 1995-10-28 1998-06-04 Jenapharm Gmbh Multi-phase preparation for contraception based on natural estrogens
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
TR200002243T2 (en) 1997-11-10 2000-12-21 Memorial Sloan-Kettering Cancer Center Process for the preparation of arsenic trioxide and their use for cancer treatment.
DE10100911A1 (en) 2001-01-11 2002-08-01 Schering Ag Process for hormone replacement therapy and its dosage form
DK1293210T3 (en) * 2001-05-23 2004-03-15 Pantarhei Bioscience Bv Hormonal Contraceptives and Methods
EP2305229A1 (en) 2001-12-05 2011-04-06 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP1648382A4 (en) * 2003-07-16 2009-09-16 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
DE102004026671A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Dosage form for hormonal contraception
DE102004026670A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499348A1 (en) * 1991-02-09 1992-08-19 Ehrlich, Marika, Dr. med. Ovulation-inhibiting agent for hormonal contraception

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499348A1 (en) * 1991-02-09 1992-08-19 Ehrlich, Marika, Dr. med. Ovulation-inhibiting agent for hormonal contraception

Also Published As

Publication number Publication date
WO1994002103A2 (en) 1994-02-03
AU4558393A (en) 1994-02-14
EP0651644A1 (en) 1995-05-10
CA2140011A1 (en) 1994-01-25
JPH07509454A (en) 1995-10-19
DE4224534A1 (en) 1994-01-27

Similar Documents

Publication Publication Date Title
RU2091069C1 (en) Agent for hormonal contraception that inhibits ovulation
AU703064B2 (en) Means and method for hormonal contraception and/or acne treatment
IL122109A0 (en) A two-stage pharmaceutical preparation for hormonal contraception and a kit containing the same
WO1994002103A3 (en) Ovulation inhibitor for hormonal contraception
UA41401C2 (en) Pharmaceutical combined contraceptive agent
AU5646296A (en) Pharmaceutical combination preparation for hormonal contraception
KR890001564A (en) Pharmaceutical dosage unit
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
MX9707009A (en) Once-a-month-injectable useful as depot contraceptive and in hormone replacement therapy for perimenopausal and premenopausal women.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA FI HU JP NO RU UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993915661

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2140011

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 374595

Country of ref document: US

Date of ref document: 19950414

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1993915661

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993915661

Country of ref document: EP